News
Zacks Investment Research on MSN19h
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives MomentumADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback